No Data
No Data
NeuroSense Therapeutics Seeking Early Regulatory Approval for Prospective ALS Treatment in Canada
NeuroSense Therapeutics Shares Are Trading Higher After the Company Announced It Initiated a Process to Seek Early Commercialization Approval for PrimeC in ALS Under Heath Canada's Notice of Compliance With Conditions Policy.
Express News | Neurosense Therapeutics: Plans to Seek Approval in Additional Countries
Express News | Neurosense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada
Express News | NeuroSense Therapeutics Announces Acceptance Of Two PrimeC Abstracts For ALS Treatment At 2024 NEALS Annual Meeting From Oct 21-24 In Clearwater, FL
NeuroSense Therapeutics Reports Mid-Year Financials
No Data
No Data